Can you take Dupilumab with Xbryk?

The denosumab in Xbryk has a major potential interaction with Hypocalcemia.

Preexisting hypocalcemia must be corrected prior to initiating treatment with denosumab. Caution should be exercised in patients predisposed to hypocalcemia and any disturbances of mineral metabolism, such as history of hypoparathyroidism, thyroid or parathyroid surgery, malabsorption syndromes, excision of small intestine, severe renal impairment or dialysis. Clinical monitoring of calcium and mineral levels (phosphorus and magnesium) are highly recommended within 14 days of denosumab injection. It is important to maintain calcium levels with adequate calcium and vitamin D supplementation.

The denosumab in Xbryk has a major potential interaction with Hypoparathyroidism.

Preexisting hypocalcemia must be corrected prior to initiating treatment with denosumab. Caution should be exercised in patients predisposed to hypocalcemia and any disturbances of mineral metabolism, such as history of hypoparathyroidism, thyroid or parathyroid surgery, malabsorption syndromes, excision of small intestine, severe renal impairment or dialysis. Clinical monitoring of calcium and mineral levels (phosphorus and magnesium) are highly recommended within 14 days of denosumab injection. It is important to maintain calcium levels with adequate calcium and vitamin D supplementation.

The denosumab in Xbryk has a moderate potential interaction with Immunodeficiency.

Denosumab should be used with caution in patients with impaired immune systems or taking concomitant immunosuppressant agents as they may be at increased risk for serious infections.

Dupilumab has a moderate potential interaction with Infection.

It is unknown if dupilumab will affect the immune response against helminth infections. Patients with preexisting helminth infections should be treated prior to therapy with dupilumab. If patients become infected while receiving dupilumab and do not respond to anthelminthic treatment, dupilumab should be discontinued until the infection resolves.

Dupilumab has a moderate potential interaction with Psoriatic Arthropathy.

Arthralgia has been reported with the use of dupilumab. Patients should be advised to report new onset or worsening joint symptoms to their health care provider.

The denosumab in Xbryk has a major potential interaction with Renal Dysfunction.

Preexisting hypocalcemia must be corrected prior to initiating treatment with denosumab. Caution should be exercised in patients predisposed to hypocalcemia and any disturbances of mineral metabolism, such as history of hypoparathyroidism, thyroid or parathyroid surgery, malabsorption syndromes, excision of small intestine, severe renal impairment or dialysis. Clinical monitoring of calcium and mineral levels (phosphorus and magnesium) are highly recommended within 14 days of denosumab injection. It is important to maintain calcium levels with adequate calcium and vitamin D supplementation.

Dupilumab has a moderate potential interaction with Rheumatoid Arthritis.

Arthralgia has been reported with the use of dupilumab. Patients should be advised to report new onset or worsening joint symptoms to their health care provider.

The denosumab in Xbryk has a major potential interaction with Thyroid Disease.

Preexisting hypocalcemia must be corrected prior to initiating treatment with denosumab. Caution should be exercised in patients predisposed to hypocalcemia and any disturbances of mineral metabolism, such as history of hypoparathyroidism, thyroid or parathyroid surgery, malabsorption syndromes, excision of small intestine, severe renal impairment or dialysis. Clinical monitoring of calcium and mineral levels (phosphorus and magnesium) are highly recommended within 14 days of denosumab injection. It is important to maintain calcium levels with adequate calcium and vitamin D supplementation.

Dupilumab has a moderate potential interaction with Visual Defect/Disturbance.

Conjunctivitis and keratitis adverse reactions have been reported with dupilumab. Care should be exercised when using this agent in patients with visual defects. Patients or their caregivers should be advised to report new onset or worsening eye symptoms to their health care provider.